Tolazoline
featured

    WARNING: This product is for research use only, not for human or veterinary use.

Hodoodo CAT#: H318884

CAS#: 59-98-3

Description: Tolazoline is a non-selective competitive α-adrenergic receptor antagonist. It is a vasodilator that is used to treat spasms of peripheral blood vessels (as in acrocyanosis). It has also been used (in conjunction with Sodium nitroprusside) successfully as an antidote to reverse the severe peripheral vasoconstriction which can occur as a result of overdose with certain 5-HT2A agonist drugs such as 25I-NBOMe, DOB and Bromodragonfly (prolonged severe vasoconstriction can lead to gangrene if untreated).

Chemical Structure

img
Tolazoline
CAS# 59-98-3
Instruction

Theoretical Analysis

Hodoodo Cat#: H318884
Name: Tolazoline
CAS#: 59-98-3
Chemical Formula: C10H12N2
Exact Mass: 160.10
Molecular Weight: 160.216
Elemental Analysis: C, 74.97; H, 7.55; N, 17.48

Price and Availability

Size Price Availability Quantity
2g USD 150
5g USD 250
10g USD 450
20g USD 750
50g USD 1650
Bulk inquiry

Synonym: Tolazoline, Benzalolin, Divascol, Pridazole, Priscol, Priscoline

IUPAC/Chemical Name: 2-benzyl-4,5-dihydro-1H-imidazole

InChi Key: JIVZKJJQOZQXQB-UHFFFAOYSA-N

InChi Code: InChI=1S/C10H12N2/c1-2-4-9(5-3-1)8-10-11-6-7-12-10/h1-5H,6-8H2,(H,11,12)

SMILES Code: C1(CC2=CC=CC=C2)=NCCN1

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 160.22 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Casbeer HC, Knych HK. Pharmacokinetics and pharmacodynamic effects of tolazoline following intravenous administration to horses. Vet J. 2013 Jun;196(3):504-9. doi: 10.1016/j.tvjl.2012.12.006. Epub 2013 Jan 12. PubMed PMID: 23321455.

2: Yokota S, Hikasa Y, Shimura I, Kusunose S. Effects of imidazoline and nonimidazoline alpha-adrenergic agents, including xylazine, medetomidine, yohimbine, tolazoline, and atipamezole, on aggregation of bovine and equine platelets. Am J Vet Res. 2013 Mar;74(3):395-402. doi: 10.2460/ajvr.74.3.395. PubMed PMID: 23438114.

3: Contreras CD, Ledesma AE, Zinczuk J, Brandán SA. Vibrational study of tolazoline hydrochloride by using FTIR-Raman and DFT calculations. Spectrochim Acta A Mol Biomol Spectrosc. 2011 Sep;79(5):1710-4. doi: 10.1016/j.saa.2011.05.041. Epub 2011 May 23. PubMed PMID: 21664861.

4: Mortenson JA, Robison JA. Tolazoline-induced apnea in mule deer (Odocoileus hemionus). J Zoo Wildl Med. 2011 Mar;42(1):105-7. PubMed PMID: 22946377.

5: Sommer CM, Radeleff BA. A novel approach for percutaneous treatment of massive nonocclusive mesenteric ischemia: tolazoline and glycerol trinitrate as effective local vasodilators. Catheter Cardiovasc Interv. 2009 Feb 1;73(2):152-5. doi: 10.1002/ccd.21811. PubMed PMID: 19156878.

6: Prado TM, DuBois WR, Ko JC, Mandsager RE, Morgan GL. A comparison of two combinations of xylazine-ketamine administered intramuscularly to alpacas and of reversal with tolazoline. Vet Anaesth Analg. 2008 May;35(3):201-7. doi: 10.1111/j.1467-2995.2007.00375.x. Epub 2008 Feb 18. PubMed PMID: 18282257.

7: DuBois WR, Prado TM, Ko JC, Mandsager RE, Morgan GL. A comparison of two intramuscular doses of xylazine-ketamine combination and tolazoline reversal in llamas. Vet Anaesth Analg. 2004 Apr;31(2):90-6. PubMed PMID: 15053746.

8: Nuntnarumit P, Korones SB, Yang W, Bada HS. Efficacy and safety of tolazoline for treatment of severe hypoxemia in extremely preterm infants. Pediatrics. 2002 May;109(5):852-6. PubMed PMID: 11986446.

9: Mpanduji DG, Bittegeko SB, Batamuzi EK, Mgasa MN, Shami CL. Comparison of the effects of atipamezole and tolazoline on analgesia, cardiopulmonary and rectal temperature changes induced by lumbosacral epidural injection of medetomidine in goats. Small Rumin Res. 2001 May;40(2):117-122. PubMed PMID: 11295393.

10: El Ries MA, Khalil S. Indirect atomic absorption determination of atropine, diphenhydramine, tolazoline, and levamisole based on formation of ion-associates with potassium tetraiodometrcurate. J Pharm Biomed Anal. 2001 Apr;25(1):3-7. PubMed PMID: 11274852.

11: Read MR, Duke T, Toews AR. Suspected tolazoline toxicosis in a llama. J Am Vet Med Assoc. 2000 Jan 15;216(2):227-9, 194. PubMed PMID: 10649759.

12: Paret G, Eyal O, Mayan H, Gilad E, Ben-Abraham R, Ezra D, Barzilay Z. Endotracheal tolazoline: pharmacokinetics and pharmacodynamics in dogs. Acta Paediatr. 1999 Sep;88(9):1020-3. PubMed PMID: 10519347.

13: Hercegová A, Sádecká J, Polonský J. Isotachophoretic determination of bisoprolol, clonidine, disopyramide and tolazoline in human fluids. Acta Pol Pharm. 1998 May-Jun;55(3):167-71. PubMed PMID: 9735699.

14: Lemke RP, al-Saedi SA, Belik J, Casiro O. Use of tolazoline to counteract vasospasm in peripheral arterial catheters in neonates. Acta Paediatr. 1996 Dec;85(12):1497-8. PubMed PMID: 9001665.

15: Lee TS, Hou X. Dual vasoactive effects of tolazoline on rabbit pulmonary arteries. J Cardiothorac Vasc Anesth. 1996 Apr;10(3):364-7. PubMed PMID: 8725418.

16: Curtis J, Palacino JJ, O'Neill JT. Production of pulmonary vasodilation by tolazoline, independent of nitric oxide production in neonatal lambs. J Pediatr. 1996 Jan;128(1):118-24. PubMed PMID: 8551401.

17: Cooper MJ, Zukin T. Tolazoline-assisted Doppler echocardiography confirming normal pulmonary venous return in a neonate with severe persistent pulmonary hypertension. Am J Perinatol. 1995 Sep;12(5):367-70. PubMed PMID: 8540945.

18: Welch JC, Bridson JM, Gibbs JL. Endotracheal tolazoline for severe persistent pulmonary hypertension of the newborn. Br Heart J. 1995 Jan;73(1):99-100. PubMed PMID: 7888273; PubMed Central PMCID: PMC483765.

19: Wilms G, Stockx L, Baert AL. Optimization of distal artery opacification in peripheral arteriography: comparison between nitroglycerin, tolazoline and buflomedyl. J Belge Radiol. 1993 Oct;76(5):311-3. PubMed PMID: 7907083.

20: Schranz D, Zepp F, Iversen S, Wippermann C, Huth R, Zimmer B, Jüngst BK, Oelert H. Effects of tolazoline and prostacyclin on pulmonary hypertension in infants after cardiac surgery. Crit Care Med. 1992 Sep;20(9):1243-9. PubMed PMID: 1521438.